Regeneron Pharma (REGN) Reiterated at Overweight by Cantor Fitzgerald Ahead of Q1 Call
April 8, 2026 8:00 AM
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $800.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
